Metrifonate v placebo at 26 weeks in patients with Alzheimer's disease†

Outcomes MetrifonatePlaceboRRI (95% CI)NNH (CI)
†Abbreviations defined in glossary; RRI, NNH, and CI calculated from data in article.
Dropouts21%12%79% (9 to 200)11 (7 to 65)
Dropouts from adverse events12%4%180% (25 to 541)13 (8 to 46)